Relationship of fibroblast growth factor 23 and fetuin-A to coronary atherosclerosis

Akın, Fatih; Çelik, Ömer; Altun, İbrahim; Ayça, Burak; Diker, Vesile Ornek; Satılmış, Seçkin; Şahin, Cem

doi:10.1016/j.jdiacomp.2015.02.013

Cited by 8 publications

(5 citation statements)

References 37 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beneficial effect was evident in both patients with and without chronic kidney disease but did seem to be numerically greater in patients with eGFR < 60 ml/ min/1.73 m 2 , who should also be expected to have the highest levels of circulating FGF-23. In patients with gestational diabetes, FGF-23 may be a promising indicator of subclinical arteriosclerosis [36], and FGF-23 has previously been shown to be positively correlated with the development of coronary atherosclerosis [37]. The anti-atherosclerotic effect of GLP-1 analogues has been suggested as an explanation for the reduction in cardiovascular morbidity and mortality associated with GLP-1 therapy [38], whereas very little data exists on how GLP-1 therapy affects the myocardial microcirculation.…”

Section: Fgf-23 and Anti-diabetes Therapymentioning

confidence: 99%

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

Sørensen

Bojer

Jørgensen

et al. 2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background The biomarker fibroblast growth factor-23 (FGF-23) has been associated with increased cardiovascular morbidity and mortality in both patients with and without type 2 diabetes. The aim of this study was to evaluate the relationship between FGF-23 and cardiac structure, function and perfusion in patients with type 2 diabetes and normal or mildly impaired kidney function. Furthermore, to investigate the association between FGF-23, anti-diabetes therapy and the classic complications and risk factors associated with type 2 diabetes. Methods In this cross-sectional study, 246 patients with type 2 diabetes underwent echocardiography and advanced cardiac magnetic resonance imaging to assess left ventricular (LV) structure and function. In addition, myocardial blood flow (MBF) during rest and pharmacological stress (adenosine 140 µg/kg/min) were evaluated in 183 of the patients. Patients with eGFR < 60 ml/min/1.73 m2 were excluded. Results Median (Q1–Q3) FGF-23 was 74 (58–91) ng/L. Patients with FGF-23 above the median had lower MBF during stress (2.3 ± 0.9 vs. 2.7 ± 0.9 ml/min/g, P = 0.001) and lower overall myocardial perfusion reserve (MPR) (2.7 ± 0.8 vs. 3.3 ± 1.1, P < 0.001). LV mass (143 ± 40 vs. 138 ± 36 g, P = 0.04) and E/e* (8.5 ± 3.2 vs. 7.6 ± 2.7, P = 0.04) were higher in patients with FGF-23 above the median. In a linear model adjusted for age, sex, eGFR and hypertension, increasing FGF-23 was associated with decreased MPR (P < 0.01, R2 = 0.11) and increased E/e* (P < 0.01, R2 = 0.07). FGF-23 was lower in patients receiving glucagon like peptide-1 (GLP-1) analogues (71 (57–86) vs. 80 (60–98) ng/L, P = 0.01) than in those who did not receive GLP-1 analogues. Conclusions In patients with type 2 diabetes and normal or mildly impaired kidney function, increased levels of FGF-23 are associated with impaired cardiac diastolic function and decreased MPR, caused by a decrease in maximal MBF during stress. Use of GLP-1 analogues is associated with decreased levels of FGF-23. Clinical trial registrationhttps://www.clinicaltrials.gov. Unique identifier: NCT02684331. Date of registration: February 18, 2016

show abstract

Section: Fgf-23 and Anti-diabetes Therapymentioning

confidence: 99%

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

Sørensen

Bojer

Jørgensen

et al. 2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…12 FGF-23 also binds to cardiac FGF receptors, activating the calcineurin -nuclear factor of activated T cells pathway implicated in vascular and valvular calcification. [13][14][15][16][17] Meanwhile, fetuin-A solubilizes calcium and phosphate, but also binds the insulin receptor, causing insulin resistance. 18 Elevated phosphate itself stimulates vascular smooth muscle cells to differentiate into an osteogenic phenotype.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis

Bortnick

Kim

et al. 2019

Atherosclerosis

View full text Add to dashboard Cite

Background and aims: Previous research has implicated dysregulation of phosphate, calciumphosphate solubilization and bone turnover in cardiovascular calcification, but epidemiologic studies evaluating their longitudinal association with valvular or annular calcification by computed tomography (CT), a highly sensitive imaging modality, are lacking. Our primary aim was to investigate the association of mineral biomarkers with incidence and progression of aortic valve calcification (AVC) and mitral annular calcification (MAC). Methods: We evaluated the association of serum FGF-23 (n=6547 participants), phosphate (n=6547), fetuin-A (n=2550) measured at baseline in the community-based Multi-Ethnic Study of Atherosclerosis with AVC and MAC on CT performed at baseline and at a median 2.4 (1.6, 3.1) years later. We used linear mixed effect models to account simultaneously for prevalence, incidence and progression of AVC and MAC. Results: After adjustment for demographic and clinical characteristics, a significant association was documented for FGF-23 with accelerated annual progression of MAC (2.83 Agatston units (AU), 95% CI=0.49, 5.17 AU, per standard deviation (18.46 pg/mL) of FGF-23), but this was not seen for phosphate or fetuin-A. None of these biomarkers was associated with accelerated annual AVC progression. Conclusions: This study provides evidence relating serum FGF-23 to accelerated annual MAC progression. Whether this mineral regulator is a risk marker or involved in pathogenesis merits further investigation.

show abstract

“…It can induce intimal thickening, intraplaque angiogenesis, and VSMC proliferation [34,35]. This phenomenon has become the basis for studies on the relationship between fibroblast growth factors (FGFs) and CAD [36,37]. It was shown that patients with ischemic heart disease exhibit elevated serum levels of bFGF [38].…”

Section: Discussionmentioning

confidence: 99%

Angiogenic and Microvascular Status Alterations after Endovascular Revascularization of Lower Limb Arteries among Patients with Diabetic Foot Syndrome: A Prospective 12-Month Follow-Up Study

Schönborn,

Gregorczyk-Maga,

Batko

et al. 2023

JCM

View full text Add to dashboard Cite

Peripheral arterial disease (PAD)-induced ischemia is an important component of diabetic foot syndrome (DFS). The results of revascularization of the lower extremity arteries (including percutaneous transluminal angioplasty [PTA]) do not always give satisfactory long-term results, which is due to many factors. The aim of the study was to investigate the alterations in selected circulating angiogenic factors and microcirculation parameters in 41 patients with DFS following PTA and analyze their relationships with clinical outcomes during 1-year follow-up. Our study revealed a general decrease in pro-angiogenic factor levels after PTA and their subsequent stabilization during subsequent observation. The results indicated a significant association between plasma circulating FGF-2 level and poor outcomes (including the incidence of restenosis/reocclusion of treated arteries) during 12 months of observation. The perioperative changes in FGF-2 showed a significant association with LDF alterations after PTA. Follow-up 1–3 months post-intervention showed a tendency towards elevated TcpO2, VEGF-A, and VEGF-R2 levels in patients free from adverse events. These results may provide a basis for further research on the potential use of selected circulating angiogenic factors for monitoring the treatment of patients with DFS following PTA.

show abstract

Relationship of fibroblast growth factor 23 and fetuin-A to coronary atherosclerosis

Cited by 8 publications

References 37 publications

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis

Angiogenic and Microvascular Status Alterations after Endovascular Revascularization of Lower Limb Arteries among Patients with Diabetic Foot Syndrome: A Prospective 12-Month Follow-Up Study

Contact Info

Product

Resources

About